4.8 Article

An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A

期刊

CELL
卷 162, 期 4, 页码 795-807

出版社

CELL PRESS
DOI: 10.1016/j.cell.2015.06.045

关键词

-

资金

  1. Angelman Syndrome Foundation
  2. Foundation for Angelman Syndrome Therapeutics
  3. Simons Foundation [274426]
  4. NIMH [R01MH093372]
  5. NINDS [R01NS085093, P30NS045892]
  6. NIH Pioneer Award from The National Institutes of Health [DP1ES024088]
  7. NIGMS [P01-GM103723]
  8. Basic and Clinical Grant from Autism Speaks [7760]
  9. Christina Castellana postdoctoral fellowship of the Foundation for Angelman Syndrome Therapeutics
  10. NICHD [T32HD040127, U54HD079124]
  11. CISMM imaging core in the Hahn lab [5P41EB002025]

向作者/读者索取更多资源

Deletion of UBE3A causes the neurodevelopmental disorder Angelman syndrome (AS), while duplication or triplication of UBE3A is linked to autism. These genetic findings suggest that the ubiquitin ligase activity of UBE3A must be tightly maintained to promote normal brain development. Here, we found that protein kinase A(PKA) phosphorylates UBE3A in a region outside of the catalytic domain at residue T485 and inhibits UBE3A activity toward itself and other substrates. A de novo autism-linked missense mutation disrupts this phosphorylation site, causing enhanced UBE3A activity in vitro, enhanced substrate turnover in patient-derived cells, and excessive dendritic spine development in the brain. Our study identifies PKA as an upstream regulator of UBE3A activity and shows that an autism-linked mutation disrupts this phosphorylation control. Moreover, our findings implicate excessive UBE3A activity and the resulting synaptic dysfunction to autism pathogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据